Tavo Biotherapeutics today announced the successful closing of a $17 million Series A financing led by Pureos Bioventures with participation by Polaris Partners and continued support from existing ...

European commercialization introduces an additional aflibercept biosimilar option for major retinal indications, potentially ...

Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing ...

Population-based studies have shown retinal disorders are the most common cause of irreversible blindness in developed countries and the second most common cause of blindness after cataracts in ...

Tavo Biotherapeutics Secures $17M to advance glaucoma and retinal disease therapies through clinical development and growth.

VEGF biosimilar has moved closer to European approval for several vision-threatening retinal diseases, including choroidal neovascularization.

Please provide your email address to receive an email when new articles are posted on . Patients with inherited retinal diseases may present with seemingly routine conditions. Look for comorbid ...

An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

An AI-assisted model based on 71 different blood proteins could help doctors better predict retinal degeneration in diabetic ...

Sunir Garg, MD, expresses excitement about attending AAO 2025 and focuses on several topics to be discussed. These include the benefits and potential vision risks of GLP-1 inhibitors in patients with ...

In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M. Moshfeghi, MD  Company to ...